A company called Kahimmune Therapeutics, which focuses on cancer treatments that boost the immune system, has made a special deal with Gustave Roussy and SATT Paris-Saclay. This deal gives Kahimmune the rights to use a special technology platform called Kahinomics, which can find unique markers in cancer cells called neoantigens. These neoantigens are created by the body’s own DNA, which hasn’t been studied much until now. Kahimmune wants to use these neoantigens to create personalized mRNA cancer vaccines. These vaccines are designed to work alongside other cancer treatments to help patients live longer and better lives. The first vaccine they’re developing will target colorectal and pancreatic cancers. According to the World Health Organization, colorectal cancer is the third most common cancer and the second leading cause of cancer deaths worldwide. Pancreatic cancer is the 13th most common cancer and the sixth leading cause of cancer deaths. Philippe Villain-Guillot, the founder and CEO of Kahimmune, said, ‘We’re focusing on cancers that are unfortunately very common and aggressive. This deal gives us a strong foundation to enter the market with a competitive edge.’ Kenza Belhaj, the director of Life Sciences Investments at SATT Paris-Saclay, added, ‘This project addresses a major medical need… the creation of Kahimmune is a crucial step in developing this innovation and making it available to patients.’